A central question in current HD drug development is whether it is better to lower total huntingtin protein (both the mutant and normal copies, as with tominersen and votoplam) or to selectively lower only the mutant allele while preserving normal huntingtin (as with WVE-003, which targets a SNP present on the mutant allele in about half of patients). Since wild-type huntingtin has important normal functions in neurons, allele-selective approaches may offer a better long-term safety profile, but only work in patients who carry the targetable genetic marker. Both strategies, along with a third approach — one-time gene therapy delivered surgically (AMT-130) — are being tested in parallel, and results across these programs over the next few years should clarify which mechanism offers the best balance of efficacy and safety.